APAC is under clinical development by Aplagon and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase II drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how APAC’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APAC overview
Recombinant protein is under development for the treatment of thrombosis, chronic kidney disease and to prevent major adverse cardiovascular events (MACE) in critical limb ischemia. The drug candidate is a heparin-containing molecule conjugated to a plasma protein which acts locally decreasing the bleeding risk and has both anti-platelet and anticoagulant (APAC) activity. It acts by targeting von Willebrand factor. It is administered through intravenous bolus route.
Aplagon overview
Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for a wide range of thromboinflammatory diseases. The company’s proprietary therapeutic APAC is a conjugate of two natural compounds such as albumin core covered by unfractionated heparin (UFH) chains. APAC can prevent and treat vascular injuries associated with thromboinflammation. Its pipeline products include Arteriovenous Fistula (AVF) for hemodialysis treatment in end-stage kidney disease and Critical Limb Ischemia (CLI) prevents amputations and other major adverse cardiovascular events in CLI patients. The company collaborates with pharmaceutical companies. Aplagon is headquartered in Helsinki, Finland.
For a complete picture of APAC’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
